Is Aurora (TSX:ACB) Doomed? Why 2020 Is a Make or Break Year for ACB Stock

The popular Aurora Cannabis stock is losing its attractiveness. After its dismal quarterly results, the company is fighting for survival. Steer clear of this weed stock in 2020, which is a ‘make or break’ year.

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

After reporting its financial and operational results for Q2 fiscal 2020, is doomsday approaching for Aurora Cannabis (TSX:ACB)(NYSE:ACB)? The erstwhile largest cannabis producer fell short of consensus estimates again. As well, a week before presenting the quarterly reports, Aurora announced the retirement of the CEO.

The number of red flags is growing following a series of setbacks. Some market analysts are saying it would be incredibly difficult for Aurora not to fall off the cliff. Others still hope for a recovery. The year 2020 will indeed be a make or break year for this weed stock.

CEO search

Aurora Cannabis is headless with the retirement of Terry Booth as CEO. If you recall, Canopy Growth was also without a leader for a time after firing company founder Bruce Linton as chief executive officer.

Aurora Executive Chairman Michael Singer will serve as interim head until a full-time captain is chosen to steer the ship. Apart from the retirement of Booth, the company is reducing full-time roles by terminating 500 staff.

With this painful move, management expects a significant decrease in quarterly selling, general, and administrative expenses. The goal is keep costs within the range of $40 million to $45 million.

Financial crunch

The financial situation of Aurora Cannabis is precarious. A goodwill write-down related to the acquired assets from Denmark and South America will amount to $775 million. But the financial crunch doesn’t end there. The company’s banking syndicate is cutting Aurora’s credit facility by $141.5 million.

While the creditor group removed the earnings ratio covenant, Aurora should at least maintain $35 million in liquidity and deliver specific levels of profit starting Q1 fiscal 2021.

Production leader no more

In 2019, Aurora was flaunting to investors its forecast of 625,000 kilos of run rate production output by June 30, 2020. It was pure bluster after all, and the company can’t claim to be the leading cannabis producer anymore. Production in Q2 fiscal 2020 was only 30,691 kilograms.

In a press release, Aurora said it was continuing to refine cultivation techniques. Here’s hoping that the company can achieve an average of 150,000 kilograms annually or better.  The target is 76% lower than the earlier promised run-rate output to investors.

Herculean task ahead

The outlook for Q3 fiscal 2020 is bleak. Aurora Cannabis expects little growth relative to the previous quarter’s cannabis revenue. The forecast is gross revenue of $65 million, 2.4% lower than $66.6 million gross sales for the past quarter. Once again, a quarterly loss is imminent.

Aurora needs to do the following: a) adjust pricing provisions to improve sales; b) sell more value-based cannabis with higher profit margins; c) grow international medical pot sales; d) increase revenue from ancillary services (counselling, testing, and hemp production); and e) hire a permanent CEO soonest.

Nearly all cannabis players are struggling. However, there’s no more room for error in so far as Aurora Cannabis concerned. Its banking syndicate is giving the company up to the first quarter of 2021 to produce results.

We’ll know by then if Aurora Canada is out of the tunnel or digging deeper.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »